Physician profile
Mark A Goldstein
NPI 1760656631
$1,669.03
in general payments reported to CMS, 2019-2025
21 companies · $452 in 2025
The $452 reported for 2025 was more than what 92% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $148 · 2021: $58.03 · 2022: $189 · 2023: $314 · 2024: $508 · 2025: $452.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,137 · Education: $137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,136.95 |
| Education | $137.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $194.03 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $189.99 | 2023-2024 | Andexxa |
| Rigel Pharmaceuticals, INC. | $157.23 | 2021-2022 | |
| Inari Medical, INC. | $150.80 | 2022-2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Medical Device Business Services, INC. | $137.01 | 2025 | Dermabond |
| Penumbra, INC. | $119.02 | 2019 | |
| Celgene Corporation | $117.57 | 2022-2025 | Reblozyl, Opdivo |
| Glaxosmithkline, LLC. | $114.29 | 2024-2025 | Ojjaara |
| E.R. Squibb & Sons, L.L.C. | $79.24 | 2022-2025 | Opdivo |
| Ethicon US, LLC | $61.87 | 2025 | Dermabond Prineo, Stratafix |
| Janssen Pharmaceuticals, INC | $56.01 | 2023-2024 | Xarelto |
| Daiichi Sankyo INC. | $51.71 | 2024-2025 | Enhertu |
| Pfizer INC. | $50.10 | 2024-2025 | |
| Bioxcel Therapeutics, INC. | $41.91 | 2023 | Igalmi |
| Array Biopharma INC | $29.14 | 2025 | Mektovi, Braftovi |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $26.89 | 2023 | Monoferric |
| Kyowa Kirin, INC. | $23.46 | 2024 | Poteligeo |
| Novartis Pharmaceuticals Corporation | $22.41 | 2022 | |
| Myriad Genetic Laboratories, INC. | $17.62 | 2024 | Myrisk |
| Biomerieux INC | $15.23 | 2019 | |
| Neos Therapeutics, LP | $13.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Goldstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.